ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1001

CKD EPI 2021 Equation for Estimation of Glomerular Filtration Rate (eGFR) Has Good Efficacy to Predict Clinical Outcomes in a Large Prospective Cohort of Adult Koreans

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Jang, So Young, Seoul National University Bundang Hospital, Seongnam, Korea (the Republic of)
  • Chin, Ho Jun, Seoul National University Bundang Hospital, Seongnam, Korea (the Republic of)
Background

A new eGFR equation using serum creatinine (CKD-EPI 2021) without race were developed by Chronic Kidney Disease Epidemiology Collaboration in 2021. We projected the changes of eGFR, CKD prevalence, and incidence of end stage renal disease (ESRD) and mortality in a large prospective cohort of adult Koreans who had voluntary health check-ups, using current (CKD-EPI 2009) and new equation (CKD-EPI 2021).

Methods

We included 112,772 adult participants, aged 18 years or older, who had voluntary routine health check-ups at three medical centers in Korea from 2003 to 2009. We compared the difference of eGFR and predictability of mortality and ESRD between eGFR values calculated by CKD-EPI 2009 and 2021. The incidence of mortality data was extracted from Statistics Korea and the ESRD data from the ESRD registry of the Korean Society of Nephrology.

Results

At baseline study, there were 60,723 males (53.8 %). The value of IDMS-traceable serum creatinine was 0.86 ± 0.21 mg/dl. Levels of eGFR at baseline study were 93.5 ± 15.6 ml/min/1.73 m2 by CKD-EPI2009, and 97.1 ± 15.0 ml/min/1.73 m2 by CKD-EPI2021. CKD stage was improved in 11,828 (10.5%) participants using eGFR calculated by CKD-EPI 2021 instead of CKD-EPI 2009, however, only 0.63 % of participants with eGFR <60 ml/min/1.73 m2 by CKD-EPI equation was reclassified into eGFR ≥60 ml/min/1.73 m2 by CKD-EPI 2021. During 11.6 ± 2.0 years, 3354 (3.00 %) subjects were dead and 151 (0.13%) subjects had end stage renal disease (ESRD) before death. Any eGFR or stage of eGFR was an independent risk factors to ESRD or mortality estimated by Cox’s hazard proportional model adjusted by related factors. AUC to estimate renal survival by eGFRs was not different between eGFRs by CKD-EPI2021 and CKD-EPI2009 [0.739 (0.687-0.790) vs 0.740(0.688-0.792), p=0.170]. p<0.001]. AUC to estimate survival by eGFRs calculated through CKD-EPI equation was slightly higher than that by CKD-EPI2021 equation [0.673(0.664-0.682) vs 0.667(0.658-0.676), p<0.001], however, the difference of AUC was negligible [standard error of AUC difference by two eGFRs; 0.96 (95% CI; 0.006-0.007)].

Conclusion

The eGFR calculated by CKD-EPI2021 was higher compared to eGFR calculated by CKD-EPI2009. The power to estimate renal survival was not different between eGFRs by CKD-EPI2021 and CKD-EPI2009.